

ICMJE DISCLOSURE FORM

Date: 6/3/2022

Your Name: Oliver A. Cornely

Manuscript Title: Infektiopedia Website - Opportunistic Infections

Manuscript Number (if known): [Click or tap here to enter text.](#)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None
Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ None
	Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis	All the listed entities made payments to the University Hospital of Cologne
3	Royalties or licenses	☒ None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☐ None	
		Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, PSI, Scynexis, Seres	All the listed entities made payments to Oliver A. Cornely
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ None	
		Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer	All the listed entities made payments to Oliver A. Cornely
6	Payment for expert testimony	☐ None	
		Cidara	The listed entity made payments to Oliver A. Cornely
7	Support for attending meetings and/or travel	☒ None	
8	Patents planned, issued or pending	☐ None	
		German Patent and Trade Mark Office	A German patent ("Geschlossene Inkubationssysteme mit verbessertem Atemwegszugang für Untersuchungsvorrichtungen", DE 10 2021 113 007.7), filed by the University of Cologne and listing Oliver A. Cornely as one of three inventors
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ None	
		Actelion, Allegra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi	All the listed entities made payments to Oliver A. Cornely

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
11	Stock or stock options	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	☒ None <table border="1"> <tr> <td>DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley</td> <td>Oliver A. Cornely is: Chair Infectious Diseases Working Party (DGHO), Advisory Committee Member (DGI), Educational Officer (ECMM), Treasurer (ISHAM), Bord of Directors Member (MSG-ERC), Editor-in-Chief for Mycoses (Wiley)</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley	Oliver A. Cornely is: Chair Infectious Diseases Working Party (DGHO), Advisory Committee Member (DGI), Educational Officer (ECMM), Treasurer (ISHAM), Bord of Directors Member (MSG-ERC), Editor-in-Chief for Mycoses (Wiley)				
DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley	Oliver A. Cornely is: Chair Infectious Diseases Working Party (DGHO), Advisory Committee Member (DGI), Educational Officer (ECMM), Treasurer (ISHAM), Bord of Directors Member (MSG-ERC), Editor-in-Chief for Mycoses (Wiley)								

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.